Allergic rhinitis in view of domestic and international documents


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Allergic rhinitis (AR) is an urgent problem of practical healthcare. Among allergic diseases, AR takes one of the leading positions in terms of its prevalence among children and adults. There are certain difficulties in diagnosis and selection of adequate treatment. The increase in the amount of information and the progress achieved in the field of studying the AR required the systematization of modern data and their presentation in consensus documents. To date, there are domestic and international documents, as well as Federal guidelines, which present algorithms for the diagnosis, therapy and prevention of AR. The article presents the main provisions concerning the use of antihistamines in patients with AR.

Full Text

Restricted Access

About the authors

V. A Revyakina

Federal Research Center for Nutrition and Biotechnology

Email: 5356797@mail.ru
Dr. Sci. (Med.), Professor, Head of the Department of Allergology

E. D Kuvshinova

Federal Research Center for Nutrition and Biotechnology

References

  1. Tong M.C.F., LinJ S.C. Epidemiology of allergic rhinitis throughout the world. In: Global atlas of rhinitis and chronic rhinosinusitis. 2015. P 62-3.
  2. Asher M.I., Montefort S., Bjorksten B., et al. Worldwide time trends in the prevalence ofsymptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733-43. doi: 10.1016/S0140-6736(06)69283-0.
  3. Katelaris C.H., Lee B.W., Potter PC., et al. Prevalence and diversity of allergic rhinitis in regions of the world beyond Europe and North America. Clin Exp Allergy. 2012;42(2):186-207. doi: 10.1111/j.1365-2222.2011.03891.x.
  4. Brozek J.L., Bousquet J., Baena-Cagnani C.E., et al. Unmet needs in severe chronic upper airway disease (SCUAD). J. Allergy Clin Immunol. 2009;126(3):466-76. Doi: 10.1016/j. jaci.2010.06.047.
  5. Brozek J.L., Bousquet J., Agache I., et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines - 2016 Revision. J. Allergy Clin Immunol. 2017;140(4):950-58. Doi: 10.1016/j. jaci.2017.03.050.
  6. Ревякина В.А., Дайхес Н.А., Геппе Н.А. и др. РАДАР. Аллергический ринит у детей. Рекомендации и алгоритм при детском аллергическом рините, 3-е, изд., перераб. и доп. М., 2020. 100 с.
  7. Аллергический ринит. Клинические рекомендации Российской ассоциации аллергологов и клинических иммунологов, Национальной медицинской ассоциации оториноларингологов, Союза педиатров России, 2020. [Электронный ресурс]. URL: https://raaci.ru/dat/ pdf/allergic_rhinitis.pdf
  8. Guyatt G., Oxman A.D., Akl E.A., et al. GRADE guidelines: 1 Introduction-GRADE evidence profiles and summary of findings tables. J. Clin Epidemiol. 2011;64(4):383-94. Doi: 10.1016/j. jclinepi.2010.04.026.
  9. Bousquet J. Schunemann H.J., Togias A., et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J. Allergy Clin Immunol. 2020;145(1):70-80. Doi: 10.1016/j. jaci.2019.06.049.
  10. Терехова Е.П., Ненашева Н.М., Терехов Д.В. Роль современных антигистаминных препаратов в лечении сезонной аллергии. Эффективная фармакотерапия. 2020;16(8):32-40. doi: 10.33978/2307-3586-2020-16-8-32-40. doi: 10.33978/2307-3586-2020-16-8-32-40.
  11. Бодня О.С., Ненашева Н.М. Антигистаминные препараты 2-го поколения при аллергическом рините: опыт реальной клинической практики. РМЖ. 2019;3:45-50.
  12. Small P., Keith PK., Kim H. Allergic rhinitis. Allergy Asthma Clin Immunol. 2018;14(Suppl. 2):51. doi: 10.1186/s13223-018-0280-7.
  13. Инструкция по медицинскому применению лекарственного препарата Зодак® капли для приема внутрь. Рег. уд. ЛС-000433.
  14. Инструкция по медицинскому применению лекарственного препарата Зодак® таблетки, покрытые оболочкой. Рег уд. П. N013867/01.
  15. Lauriello M., et al. A two-year course of specific immunotherapy or of continuous antihistamine treatment reverse eosinophilic inflammation in severe persistent allergic rhinitis. Acta Otorhinolaryngol. Ital. 2005;25(5):284-91.
  16. Falliers C.J., Brandon M.L., Buchman E., et al. Double-blind comparison of cetirizine and placebo in the treatment of seasonal rhinitis. Ann Allergy. 1991;66(3):257-62.
  17. Grant J.A., et al. A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects. Allergy. 1999:54:700-7. doi: 10.1034/j.1398-9995. 1999.00032.x.
  18. Pacor M.L., Biasi D., Carletto A., Corrocher R. The efficacy of cetirizine in the treatment of perennial allergic rhinitis. Recenti Prog Med. 1999;90(6):325-26.
  19. Зайцева С.В. и др. Современные возможности терапии поллиноза у детей. РМЖ. 2012;6:314.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies